Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Allena Pharmaceuticals, Inc. engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Sudbury, MA.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.